Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • AstraZeneca drug...

    AstraZeneca drug selumetinib fails in lung cancer study

    Written by savita thakur thakur Published On 2016-08-09T15:28:28+05:30  |  Updated On 9 Aug 2016 3:28 PM IST
    AstraZeneca drug selumetinib fails in lung cancer study

    AstraZeneca's cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.


    Hopes for the medicine had already been reduced after it failed in another study for treating a rare cancer of the eye in July 2015, although it may still have a role in a type of thyroid cancer and in cancers growing along nerve tissue.


    Selumetinib is viewed as less important than AstraZeneca's recently launched cancer drugs Tagrisso and Lynparza, and its closely watched experimental product durvalumab.


    Hopes for immunotherapy medicine durvalumab have been fuelled in recent days by the failure of Bristol-Myers Squibb's Opdivo in previously untreated lung cancer patients. Analysts believe this could open up the market opportunity for AstraZeneca.


    Selumetinib belongs to a class of cancer drugs known as MEK inhibitors.


    The British drugmaker said that when selumetinib was given with chemotherapy it did not slow lung cancer progression as hoped or have a significant effect on overall survival.


    Sean Bohen, head of medicines development, described the Phase III trial result as "disappointing", since the drug had shown promise in earlier Phase II results in non-small cell lung cancer.


    AstraZeneca is relying on oncology treatments to revive its fortunes following a wave of patent expiries.

    AstraZeneca'sBristol-Myerscancercancer druglung cancernon-small cell lung cancerOpdivoSean BohenSelumetinibthyroid cancer
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok